Onc Now | Episode 18
In the first of this two-part series, host Jonathan Sackier is joined by Bradley Monk, a pioneering figure in gynaecologic oncology. In Part 1, they discuss key updates from the European Society of Gynaecological Oncology (ESGO) Congress, including the updated ESGO-ESTRO-ESP endometrial cancer guidelines and the latest results from the KEYLYNK-001 study in ovarian cancer. With reflections from his three-decade career, Monk provides actionable takeaways for clinicians and researchers alike. Stay tuned for Part 2, where they delve into insights from SGO 2025.
Apple | Spotify | Amazon Music | Youtube | Download MP3 (18 mins)
Bradley Monk is a leading gynaecologic oncologist and Medical Director of Late-Phase Clinical Research at Florida Cancer Specialists. With over 30 years of experience, he has held major academic roles at UC Irvine and Creighton University. Monk has led pivotal trials in ovarian and cervical cancer, contributing to the global approval of numerous therapies. He is internationally recognised for his leadership in gynaecologic cancer research and clinical innovation.
Timestamps:
00:00 – Quickfire questions
04:55 – Career milestones
07:10 – ESGO 2025 standout sessions
09:52 – KEYLYNK-001 trial & takeaways
13:52 – New endometrial cancer staging
